Podcasts about sotrovimab

In his weekly clinical update Dr. Griffin discusses the efficacy and safety of two RSV vaccines in older adults, health care vaccine mandate remains as some push for an end, past SARS-CoV-2 infection protection against re-infection, a third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, effect of higher-dose Ivermectin for 6 Days vs placebo on time to sustained recovery in outpatients with COVID-19, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, serological response to vaccination in post-acute sequelae of COVID, sex differences in cardiovascular complications and mortality in hospital patients with COVID-19, association of COVID-19 vaccination with risk for incident diabetes after COVID-19, postacute sequelae of SARS-CoV-2 in university setting, the CDC's long-Covid deception, and podcast companies, once walking on air, feel the strain of gravity. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode RSV prefusion F protein vaccine in older adults (NEJM) Efficacy and safety of an Ad26.RSV.preF–RSV preF protein vaccine (NEJM) Health care vaccine mandate remains as some push for an end (AP) Past SARS-CoV-2 infection protection against re-infection (The Lancet) A third vaccine dose equalizes the levels of effectiveness and immunogenicity of COVID-19 vaccine regimens (medRxiv) Sotrovimab retains activity against SARS-CoV-2 Omicron variant in primate model (bioRxiv) Effect of higher-dose Ivermectin for 6 days vs placebo in patients with COVID-19 (JAMA) Viral burden rebound in patients with COVID-19 receiving oral antivirals (The Lancet) Serological response to vaccination in post-acute sequelae of COVID (BMC) Sex differences in cardiovascular complications and mortality in patients with COVID-19 (BMI) Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 (JAMA) Postacute sequelae of SARS-CoV-2 in university setting (CDC) The CDC's Long-Covid deception (WSJ) Podcast companies, once walking on air, feel the strain of gravity (NYT) Contribute to our ASTMH fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 986 Don't crush Paxlovid (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans, time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir, COVID drug Paxlovid was hailed as a game-changer, what happened?, the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID — even with a mild case. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Infectiousness of breakthrough infections & reinfections during Omicron wave (Nature) Virological characteristics of the SARS-CoV-2 XBB variant (bioRxiv) Antibody evasion properties of BQ and XBB subvariants (Cell) Comparative effectiveness of third doses of mRNA vaccines in US veterans (Nature) Time to negative PCR conversion among high-risk patients treated by Sotrovimab or Nirmatrelvir (CMI) Paxlovid patient eligbiliity screening checklist (FDA) COVID drug Paxlovid was hailed as a game-changer. What happened? (Nature) Fc-effector function of COVID-19 convalescent plasma contributes to treatment efficacy (Cell) SARS-CoV-2 infection and persistence in the human body and brain at autopsy (Nature) Long-term cardiovascular outcomes of COVID-19 (Nature) Heart-disease risk soars after COVID (Nature) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 972 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses the four things to know about RSV, the burden of respiratory syncytial virus in healthy term-born infants in Europe, the diagnostic accuracy of rapid diagnostic tests for Ebola virus disease, evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox, tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations, acute and postacute sequelae associated with SARS-CoV-2 reinfection, clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy, maternal antibody response and transplacental transfer following SARS-CoV-2 infection or vaccination in pregnancy, impact of community masking on COVID-19, Lifting Universal Masking in Schools – Covid-19 Incidence among Students and Staff, systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community, early adoption of anti–SARS-CoV-2 pharmacotherapies among us veterans with mild to moderate COVID-19, evaluation of viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants, monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy, twice daily oral zinc in the treatment of patients with COVID-19, cognitive deficits in long Covid-19, severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration, and long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Four things to know about RSV (Gates Foundation) The burden of RSV in healthy term-born infants in Europe (The Lancet) Diagnostic accuracy of rapid tests for Ebola (CMI) Accuracy of self-collected swabs for diagnosis of Monkeypox (CID) Tecovirimat is effective against human monkeypox virus in vitro (Nature) Acute and postacute sequelae associated with SARS-CoV-2 reinfection (NatureMedicine) SARS-CoV-2 infection and recovery in lung transplant recipients (Transplant Infectious Diseases) Effectiveness of third COVID-19 vaccination during pregnancy (Nature Communications) Maternal antibody response and transplacental transfer following infection or vaccination (CID) Impact of community masking on COVID-19 (Science) Lifting universal masking in schools (NEJM) Bebtelovimab fact sheet for providers (FDA) Effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 (medRxiv) Effectiveness of Sotrovimab and Molnupiravir for prevention of severe COVID-19 outcomes (BMJ) Early adoption of Anti–SARS-CoV-2 pharmacotherapies among US veterans (JAMA) PAXLOVID patient eligibility screening checklist (FDA) Viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants (medRxiv) Monoclonal antibodies for treatment of SARS-CoV-2 during pregnancy (Annals of Internal Medicine) Remdesivir fact sheet for providers (Veklury)  Twice daily oral zinc in the treatment of patients with COVID-19 (CID)  Cognitive deficits in long COVID-19 (NEJM) Severe Neuro-COVID associated with peripheral immune signatures, autoimmunity and neurodegeneration (Nature Communications) Long-lasting symptoms after an acute COVID-19 Infection (JAMA) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 955 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Additional resources OHA COVID-19 vaccine website: covidvaccine.oregon.gov OHA Facebook  Safe+Strong website Ask a Black Doctor on The Numberz REACH webpage and REACH Facebook Treatments for COVID-19 Q1: I have heard that some people can get treated for COVID-19. What treatments are available and how are they different from vaccines? Yes – treatments for COVID-19 are available for some people. Some treatments are given in the hospital, some are infusions and some are pills you can take at home. They are all in short supply and currently available to people who are high risk of severe disease.  Vaccines introduce your immune system to a protein from the virus, allowing you to build up antibodies without being infected. Vaccination can also boost any natural immunity a person may have from being previously infected.  When somebody with sufficient antibodies is exposed to COVID-19, they immediately fend off the virus, which prevents infection. As antibody levels drop, the virus may be able to infect the person but the immune system still has a decent chance to fight COVID-19 and prevent severe infection.  Booster shots rebuild antibodies quickly, within a few days, even quicker than the original vaccination. This rapid rebuild also happens when an unvaccinated person previously infected with the COVID-19 virus gets their first vaccination. So be sure to get vaccinated and boosted, even if you have previously been infected with COVID-19. Treatments do not replace vaccination, which remains the most important step we can take to protect ourselves and our loved ones.  If someone can't get vaccinated, there is a treatment available that helps the body fight the virus that causes COVID-19.  Treatment for COVID-19 must take place shortly after someone has tested positive. If you've tested positive for COVID or have symptoms, contact your doctor right away. Q2: Someone was telling me about the federal Test to Treat program. Is this a program for everyone? The Test to Treat program connects people that are at high risk of severe illness from COVID-19 with the right treatment. It provides people a place to go to get tested, receive a prescription for a treatment, and fill that prescription all at one location. The program is intended for people that do not have a doctor or who cannot easily get in to see their doctor. However, anyone can receive treatment at a Test to Treat site. To participate, a person can use the Test to Treat Locator to find a site, or call 1-800-232-0233. These sites receive their therapeutics from the federal government. OHA is working on adding additional sites that fit federal criteria to be a Test to Treat site.   Q3: If treatments support defense against COVID-19, why aren't they available to everyone? There a few reasons why treatments are not available to everyone. First, vaccines have proven to be the best defense against COVID-19. Get vaccinated and then boosted. Also, don't forget your flu shot. Secondly, because of nationwide shortages, treatments are not widely available. Finally, it is all based on eligibility. A healthcare provider determines eligibility based on your medical profile. They will consider things like if you cannot get vaccinated due to health conditions or if you had a bad reaction to the vaccine or if you need additional treatment due to a weakened immune system. Only a healthcare provider can assess if you are eligible. Q3: Are treatments safe?  Depending on your medical history, certain treatments are not recommended. To determine which treatment is right for you, consult your doctor. You should also always check that your information is from a trusted source. If you have questions about any medication, contact the FDA's Division of Drug Information at 301-796-3400 or druginfo@fda.hhs.gov. Q5: What are the names of the FDA approved or authorized treatments and once I take them, how do they work in my body to fight COVID-19? The FDA has authorized two oral antiviral medications, one from Pfizer named Paxlovid. The other from Merck named Molnupiravir. With either one, they must be taken as soon as possible after a positive COVID-19 test and within the first five days of symptoms to be effective.  Paxlovid works by stoping the replication of the COVID-19 virus in the body by binding to an enzyme that disrupts the virus' ability to mutate and keeps certain viral proteins from forming correctly.   Molnupiravir interrupts replication of the virus' genetic material by introducing mutations. As the virus copies itself, it gets so mutated that it can no longer function.   The same thing happens with the FDA approved antiviral drug Remdesivir, known as Veklury, it also acts on the virus' genetic material, blocking its ability to mutate. It is administered by injection into the vein through an IV. Monoclonal antibodies (mAbs) are authorized for use to treat COVID-19. They work by mimicking the antibodies your body produces in response to a virus. These molecules are produced in a laboratory and they work to block the COVID-19 virus from entering your cells. Monoclonal antibody treatment is a fluid given using a needle either into a vein (infusion) or under the skin (subcutaneously). Your healthcare provider or the site where you will be getting treatment will explain which treatment you will get. For both procedures, needles are used by a trained medical professional. If you are unvaccinated, you should wait 90 days after your treatment to get the vaccine. Regen-Cov, Sotrovimab, Bebtelovimab and Evusheld are all monoclonal antibodies. Sotrovimab is effective against infection by the  Omicron variant.  Q6: Finally, April is National Minority Health Month how can I get involved? This year the U.S. Department of Health and Human Services (HHS) Office of Minority Health (OMH) and its partners are highlighting the important role community plays in helping to reduce health disparities in racial and ethnic minority and American Indian/Alaska Native groups. The theme for this year is Give Your Community a Boost!  To support COVID-19 vaccination and boosting, OMH invites you to #BoostYourCommunity by using, sharing, and attending National Minority Health Month (NMHM) resources and events with your organization, communities, and network!  If you are not insured, you might qualify for the Oregon Health Plan, which covers COVID-19 vaccines, boosters, treatment and home tests. It also covers regular check-ups, prescriptions, mental health care, addiction treatment, dental care and more. To see if you qualify and to learn more go to OHP.Oregon.gov and click Apply for OHP. You can also call 800-699-9075 or find a local community partner at bit.ly/ohplocalhelp for help.Document accessibility: For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the Health Information Center at 1-971-673-2411, 711 TTY or COVID19.LanguageAccess@dhsoha.state.or.us.

The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including:BebtelovimabCilgavimab/tixagevimabSotrovimabPresenter:Gregory Huhn, MD, MPHTMAssociate ProfessorDepartment of Infectious DiseasesRush University Medical CenterSenior Director of HIV ServicesDepartment of Infectious DiseasesCook County HealthChicago, IllinoisReview the downloadable slidesets at: https://bit.ly/3xOfu1ALink to full program: https://bit.ly/3EBdf38

This week on Pharm5: FDA and DEA warn of online CII sales Ultomiris (ravulizumab) improves ADLs and QOL for up to 60 weeks in patients with myasthenia gravis Fidaxomicin's biomolecular specificity to C. diffunveiled Sotrovimab has lost its EUA for treatment of COVID-19 Results from Phase II of ASHP's Residency Match Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD References: McCarthy L-J. FDA and DEA warn online pharmacies illegally selling Adderall to consumers. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-and-dea-warn-online-pharmacies-illegally-selling-adderall-consumers. Published April 12, 2022. Accessed April 12, 2022. Ultomiris® (ravulizumab-CWVZ) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks. AstraZeneca US. https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-demonstrated-sustained-improvements-in-functional-activities-and-quality-of-life-in-adults-with-generalized-myasthenia-gravis-through-60-weeks.html. Published April 6, 2022. Accessed April 14, 2022. Ultomiris (ravulizumab-CWVZ). Package insert. Alexion Pharmaceuticals, Inc; 2018. Cao X, Boyaci H, Chen J, Bao Y, Landick R, Campbell EA. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature. April 2022. doi:10.1038/s41586-022-04545-z Rockefeller University. How a narrow-spectrum antibiotic takes aim at C. Diff. EurekAlert! https://www.eurekalert.org/news-releases/948950. Published April 6, 2022. Accessed April 14, 2022. Center for Drug Evaluation and Research. FDA updates Sotrovimab Emergency Use Authorization. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization. Published April 5, 2022. Accessed April 14, 2022. Person, Kavya B AM. Worldwide covid cases surpass 500 mln as Omicron variant BA.2 surges. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/worldwide-covid-cases-surpass-500-mln-omicron-variant-ba2-surges-2022-04-14/. Published April 14, 2022. Accessed April 14, 2022. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published April 13, 2022. Accessed April 14, 2022. ASHP Match Statistics. ASHP Match | Statistics of the Match. https://natmatch.com/ashprmp/stats.html. Published April 13, 2022. Accessed April 14, 2022.

AMA CXO Todd Unger reviews COVID-19 vaccine numbers and trending topics related to the pandemic over the past week with AMA Director of Science, Medicine and Public Health Andrea Garcia. Also covering updates from FDA's vaccine advisory committee meeting regarding a revised version of the COVID vaccine for fall, the FDA suspending use of a monoclonal antibody drug by GlaxoSmithKline known as sotrovimab to treat high-risk COVID-19 patients in the U.S. because it's unlikely to be effective against BA.2, and a clinical trial published in NEJM confirms that the anti-parasitic drug, ivermectin, showed no sign of alleviating COVID.

Cronies say Sotrovimab treatment is ineffective against the BA 2 variant. At this point do we believe anything they say? --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Editor's Summary by Christopher Muth, MD, Senior Editor of JAMA, the Journal of the American Medical Association, for the April 5, 2022 issue.

A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast media containing iodine.

The sub-variant of Omicron, known at the moment as BA2, is being blamed for a rise in cases in NSW and likely in other states and territories.And overseas, Hong Kong is struggling with a wave which is killing more and more people due to low levels of vaccination in high risk age groups.So what could the sub-variant mean for Australia as the weather slowly cools down and we enter darker, cooler times?Also on today's show:* China goes into lockdown in several big cities* Australian researchers have uncovered resistance mutations to Sotrovimab

The sub-variant of Omicron, known at the moment as BA2, is being blamed for a rise in cases in NSW and likely in other states and territories. And overseas, Hong Kong is struggling with a wave which is killing more and more people due to low levels of vaccination in high risk age groups. So what could the sub-variant mean for Australia as the weather slowly cools down and we enter darker, cooler times? Also on today's show: * China goes into lockdown in several big cities * Australian researchers have uncovered resistance mutations to Sotrovimab

The sub-variant of Omicron, known at the moment as BA2, is being blamed for a rise in cases in NSW and likely in other states and territories. And overseas, Hong Kong is struggling with a wave which is killing more and more people due to low levels of vaccination in high risk age groups. So what could the sub-variant mean for Australia as the weather slowly cools down and we enter darker, cooler times? Also on today's show: * China goes into lockdown in several big cities * Australian researchers have uncovered resistance mutations to Sotrovimab

In this Journal Jam podcast we dig deep into the science of FDA-approved outpatient medications for COVID with 3 critical appraisal masters: Dr. Andrew Morris, Dr. Rohit Mohindra and Dr. Justin Morgenstern. What is the evidence for the neutralizing monoclonal antibody medications like Sotrovimab? The nucleoside analogs like Remdesivir and Paxlovid? The inhaled corticosteroids like Budesonide and Ciclesonide? The SSRIs like Fluvoxamine? As you'll hear, there are many ways to interpret the data and a variety of philosophies on prescribing medications that have not had enough time to be studied adequately in a pandemic where millions of lives have been lost and we do not have much to offer patients to reduce morbidity and mortality... The post JJ 20 Outpatient Medications for COVID-19 appeared first on Emergency Medicine Cases.

Republicans are accusing the Biden administration of racism — against white people. The FDA's December guidance on the use of sotrovimab — the only monoclonal antibody proven effective against Omicron — notes people of color may be at higher risk for severe Covid-19 and said it's one factor among several that doctors can consider when doling out the drug, given that Sotrovimab remains in short supply. But, it's now become the latest political talking point for Republicans, looking to energize their base ahead of the midterm elections, and the political backlash is already fraying patchwork policy at the state level. Megan Messerly reports.

The wave of covid cases of the omicron variant continues to spread worldwide, and the covid-19 vaccines (and boosters) clearly aren't preventing infection and spread of it. Only one kind of monoclonal antibody treatment, Sotrovimab by GlaxoSmithKline, tends to be effective against this variant, though it's in short supply. Vitamin D levels need to be …

Welcome to Episode 13 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 13 of “The 2 View” – Nystagmus, SCAD, Sotromivab, Paxlovid, Molnupivarvir, and more. Nystagmus Mehar A. CanadiEM Frontline Primer - Vertigo workup. CanadiEM. Published April 25, 2020. Accessed January 11, 2022. https://canadiem.org/canadiem-frontline-primer-vertigo/ Nystagmus. NeurologyNeeds.com. Accessed January 11, 2022. https://www.neurologyneeds.com/neurological-examination-tips-tricks/nystagmus/ Nystagmus. The Proceduralist. Published January 10, 2022. Accessed January 11, 2022. https://www.youtube.com/watch?v=fW3sVsNgJ2k Talmud JD, Coffey R, Edemekong PF. Dix Hallpike Maneuver. NCBI. StatPearls Publishing. Last Update December 19, 2021. Accessed January 11, 2022. https://www.ncbi.nlm.nih.gov/books/NBK459307/ SCAD Beardsell L. Preventing mid-life spontaneity becoming a crisis - SCAD as a serious cause of chest pain. St Emlyn's. St.Emlyn's Emergency Medicine. Published May 29, 2021. Accessed January 11, 2022. https://www.stemlynsblog.org/scad/ Durrani M. Spontaneous Coronary Artery Dissection (SCAD). REBEL EM - Emergency Medicine Blog. Published October 19, 2020. Accessed January 11, 2022. https://rebelem.com/spontaneous-coronary-artery-dissection-scad/ Hayes SN, Tweet MS, Adlam D, et al. Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review. J Am Coll Cardiol. Published August 2020. Accessed January 11, 2022. https://www.jacc.org/doi/abs/10.1016/j.jacc.2020.05.084 Johnson AK, Tweet MS, Rouleau SG, Sadosty AT, Raukar NP. 243 Spontaneous Coronary Artery Dissection in the Emergency Department: The Elusive Dissection. Ann Emerg Med. Published October 1, 2020. Accesseed January 11, 2022. https://www.annemergmed.com/article/S0196-0644(20)31003-9/fulltext#relatedArticles Kim ESH. Spontaneous Coronary-Artery Dissection. N Engl J Med. Published December 10, 2020. Accessed January 11, 2022. https://www.nejm.org/doi/full/10.1056/NEJMra2001524 Sotromivab, Paxlovid and Molnupivarvir Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. Published November 5, 2020. Accessed January 11, 2022. https://www.nejm.org/doi/full/10.1056/nejmoa2007764 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. Published online December 16, 2021. Accessed January 11, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2116044 PAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets): Now Authorized for Emergency Use. For Patients. Pfizer. Covid19oralrx-patient.com. Accessed January 11, 2022. https://www.covid19oralrx-patient.com/ Sotrovimab. Sotrovimab.com. GSK. Accessed January 11, 2022. https://www.sotrovimab.com/ Guest Interview: JIM ROBERTS - IVERMECTIN Bryant A, Lawrie T, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics. Lww.com. Published July/August 2021. Accessed January 11, 2022. https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectinforpreventionandtreatment_of.7.aspx Em-news.com. Accessed January 11, 2022. http://www.em-news.com Kory P MD, Meduri GU MD, Iglesias J, et al. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Published online 2020. Updated January 16, 2021. Accessed January 11, 2022. https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf Mike & Martha's Something Sweet: Safest Countries in the World in 2021 Safest Countries in the World 2021. Worldpopulationreview.com. Accessed January 11, 2022. https://worldpopulationreview.com/country-rankings/safest-countries-in-the-world Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in – this month we are giving away 20% off of our July Bootcamp Course and lunch with the faculty! Win and join us in Vegas this summer – come and share your ER experiences with us over a good meal.

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:Direct-acting, small-molecule antiviral agents such as   molnupiravir, nirmatrelvir + ritonavir, and remdesivirMonoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimabPresenter:Arthur Kim, MDAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Viral Hepatitis ClinicDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsReview the downloadable slidesets at:https://bit.ly/3FXc90whttps://bit.ly/32tp2BTLink to full program: https://bit.ly/3Ix8uZg

What is sotrovimab, and how does it work against Covid? Why is it called sotrovimab and not sotrolimab? How come it has a risk reduction of 85% and 6% yet these are both true and both mean the same thing? And if you were asked how good it might be for your patient, what would you say?

La Organización Panamericana de la Salud (OPS), 11 de enero de 2022. Publica, la 31ª edición de la base de datos de evidencia sobre posibles opciones terapéuticas para COVID-19. Examina 171 opciones terapéuticas. Según el portal de búsqueda de la Plataforma Internacional de Registro de Ensayos Clínicos (ICTRP) de la OMS, se están investigando cientos de posibles tratamientos o sus combinaciones en más de 10.000 ensayos clínicos y estudios observacionales. Treinta hallazgos clave. 1• Corticosteroides: 2• Remdesivir: 3• Hidroxicloroquina, interferón beta 1-a y lopinavir-ritonavir: 4• Antibióticos: 5• Plasma de convalecientes 6• Tocilizumab: 7• Sarilumab: 8• Anakinra: 9• Tofacitinib: 10• Colchicina: 11• Ivermectina: 12• Favipiravir: 13• Sofosbuvir con o sin daclatasvir, ledipasvir, velpatasvir o ravidasvir: 14• Baricitinib: 15• Casirivimab e Imdevimab (REGEN-COV 16• Bamlinivimab con o sin etesevimab 17• Sotrovimab: 18• Regdanvimab 19• Proxalutamide: 20• Dapagliflozina 21• Trasplante de células madre mesenquimatosas 22• Corticosteroides inhalados 23• Fluvoxamina: 24• Lenzilumab: 25• Fragmentos policlonales de anticuerpos equinos (INM005): 26• Famotidina: 27• Anticoagulantes: 28• Antiinflamatorios no esteroideos (AINE): 29• IECA y ARB 30• Molnupiravir: Conclusiones. 1• La Organización Panamericana de la Salud (OPS) hace seguimiento en todo momento de la evidencia en relación con cualquier posible intervención terapéutica. A medida que se disponga de evidencia nueva, la OPS la incorporará con rapidez y actualizará sus recomendaciones, especialmente si dicha evidencia se refiere a grupos en situación de vulnerabilidad como los niños y niñas, las mujeres embarazadas, las personas mayores o los pacientes inmunocomprometidos, entre otros. 2• La OPS también tiene en cuenta las diferencias en el impacto de la COVID-19 sobre las minorías y los diferentes grupos étnicos. En consecuencia, la Organización recopila constantemente información que pueda servir para mitigar el exceso de riesgo de enfermedad grave o muerte de estas minorías. Estos grupos sufren inequidades sociales y estructurales que conllevan una carga de enfermedad desproporcionada. 3• La seguridad de los pacientes afectados por la COVID-19 es una prioridad clave de la mejora de la calidad de la atención y los servicios de salud. 4• Sigue siendo apremiante la necesidad de elaborar ensayos clínicos aleatorizados de alta calidad que incluyan pacientes con COVID-19 a fin de poder desarrollar estrategias de manejo confiables. La importancia de los ensayos clínicos controlados aleatorizados con un diseño adecuado es fundamental en la toma de decisiones basadas en la evidencia. Hasta el momento, la mayoría de la investigación en el campo de la COVID-19 tiene muy baja calidad metodológica, lo que dificulta su identificación y validación. Urge incrementar la transparencia y plantear estudios de más calidad. REFERENCIA. https://iris.paho.org/handle/10665.2/52719 ADAPTACION PARA AUDIO-OYENTES: Medicina en una página. Dirección y Conducción: John Jarbis García Tamayo.

En el video de hoy revisamos 2 medicamentos más recomendados por disminuir la mortalidad y las complicaciones de la Covid-19, el baricitinib y el sotrovimab.Checa el comunicado aquí: https://www.who.int/news/item/14-01-2022-who-recommends-two-new-drugs-to-treat-covid-19Checa el video aquí: https://youtu.be/0Q9ghcRoHzEVisita nuestra tienda en línea para comprar nuestros libros y material educativo:https://bit.ly/3i6eAnGSi necesitas una consulta aquí nos puedes encontrar:http://bit.ly/3aUSt12Ayúdanos a encontrar los mejores hospitales para estudiar:https://bit.ly/36o82LXUnete al equipo de Mecenas en YouTube desde 1 dolar al mes: http://bit.ly/2O1AtsXSupport the show (https://www.paypal.com/donate?hosted_button_id=2ENWQ7V289PBE)

Machache kati ya mengi tuliyokuandalia hii leo kutoka UN WHO yapendekeza dawa mbili mpya za kutibu wagonjwa wa COVID-19 ambazo ni Baricitinib ya kumeza kwa ajili ya kutibu wagonjwa mahututi  wa COVID-19 na nyingine ni Sotrovimab ya sindano ambayo ni kwa ajili ya wagonjwa wasio katika hali mbaya sana. Na katika mada kwa kina tunaelekea mkoani  Ruvuma nchini Tanzania kumulika mradi wa nishati salama uliofanikishwa na Umoja wa Mataifa kwa kuwaunga mkono wenyeji.

Play during opening: 0:00-0:10 …and more on today's CrossPolitic Daily News Brief. This is Toby Sumpter. Today is Friday, January 14, 2022.  SCOTUS Blocks Biden VAX Mandate & Upholds Healthcare Worker Mandate https://www.cnbc.com/2022/01/13/supreme-court-ruling-biden-covid-vaccine-mandates.html The Supreme Court on Thursday blocked the Biden administration from enforcing its sweeping vaccine-or-test requirements for large private companies, but allowed a vaccine mandate to stand for medical facilities that take Medicare or Medicaid payments. The rulings came three days after the Occupational Safety and Health Administration's emergency measure for businesses started to take effect. The mandate required that workers at businesses with 100 or more employees get vaccinated or submit a negative Covid test weekly to enter the workplace. It also required unvaccinated workers to wear masks indoors at work. “Although Congress has indisputably given OSHA the power to regulate occupational dangers, it has not given that agency the power to regulate public health more broadly,” the court wrote in an unsigned opinion. “Requiring the vaccination of 84 million Americans, selected simply because they work for employers with more than 100 employees, certainly falls in the latter category,” the court wrote. President Joe Biden, in a statement, said the Supreme Court chose to block requirements that are life-saving for workers. Biden called on states and businesses to step up and voluntarily institute vaccination requirements to protect workers, customers and the broader community. “The Court has ruled that my administration cannot use the authority granted to it by Congress to require this measure, but that does not stop me from using my voice as President to advocate for employers to do the right thing to protect Americans' health and economy,” Biden said. In a separate, simultaneously released ruling on the administration's vaccination rules for health-care workers, a 5-4 majority sided with the Biden administration. “We agree with the Government that the [Health and Human Services] Secretary's rule falls within the authorities that Congress has conferred upon him,” said the majority, writing that the rule “fits neatly within the language of the statute.” “After all, ensuring that providers take steps to avoid transmitting a dangerous virus to their patients is consistent with the fundamental principle of the medical profession: first, do no harm,” the majority opinion read. Justices Clarence Thomas, Samuel Alito, Neil Gorsuch and Amy Coney Barrett, four of the six conservatives on the nine-seat bench, dissented. Kavanaugh and Roberts joined the three liberals to enforce this ruling. “I do not think that the Federal Government is likely to be able to show that Congress has authorized the unprecedented step of compelling over 10,000,000 healthcare workers to be vaccinated on pain of being fired,” Alito wrote in his dissent. FDA Issues Racist Triage Rationing for COVID Treatments https://freebeacon.com/coronavirus/food-and-drug-administration-drives-racial-rationing-of-covid-drugs/ Fron the Washington Free Beacon: In New York, racial minorities are automatically eligible for scarce COVID-19 therapeutics, regardless of age or underlying conditions. In Utah, "Latinx ethnicity" counts for more points than "congestive heart failure" in a patient's "COVID-19 risk score"—the state's framework for allocating monoclonal antibodies. And in Minnesota, health officials have devised their own "ethical framework" that prioritizes black 18-year-olds over white 64-year-olds—even though the latter are at much higher risk of severe disease. These schemes have sparked widespread condemnation of the state governments implementing them. But the idea to use race to determine drug eligibility wasn't hatched in local health departments; it came directly from the federal Food and Drug Administration. When the FDA issued its emergency use authorizations for monoclonal antibodies and oral antivirals, it authorized them only for "high risk" patients—and issued guidance on what factors put patients at risk. One of those factors was race. The FDA "fact sheet" for Sotrovimab, the only monoclonal antibody effective against the Omicron variant, states that "race or ethnicity" can "place individual patients at high risk for progression to severe COVID-19." The fact sheet for Paxlovid, Pfizer's new antiviral pill, uses the Centers for Disease Control and Prevention's definition of "high risk," which states that "systemic health and social inequities" have put minorities "at increased risk of getting sick and dying from COVID-19." The guidance sheets are nonbinding and do not require clinicians to racially allocate the drugs. But states have nonetheless relied on them to justify race-based triage. "The FDA has acknowledged that in addition to certain underlying health conditions, race and ethnicity ‘may also place individual patients at high risk for progression to severe COVID-19,'" Minnesota's plan reads. "FDA's acknowledgment means that race and ethnicity alone, apart from other underlying health conditions, may be considered in determining eligibility for [monoclonal antibodies]." Utah's plan contains similar language. In a section on the "Ethical Justification for Using Race/Ethnicity in Patient Selection," it notes that the FDA  "specifically states that race and ethnicity may be considered when identifying patients most likely to benefit from this lifesaving treatment." The FDA declined to comment on either state's plan, saying only that "there are no limitations on the authorizations that would restrict their use in individuals based on race." The triage plans are part of a broader push to rectify racial health disparities through race-conscious means. In March of last year, for example, two doctors at Brigham and Women's Hospital in Boston outlined an "antiracist agenda for medicine" that involved "offering preferential care based on race." And last year, Vermont and New Hampshire both gave racial minorities priority access to the COVID-19 vaccine, resulting in at least one formal civil rights complaint against New Hampshire. The trend has alarmed Roger Severino, the former civil rights director at the Department of Health and Human Services, who called racial preferences in medicine a "corrosive and grossly unfair" practice. "Our civil rights laws are not suspended during a public health emergency," Severino said. "We should never deny someone life-saving health care because of the color of their skin." The triage plans show how federal guidelines can encourage this sort of race discrimination. They also suggest that the FDA is making political judgments, not just scientific ones. "They're injecting politics into science," said a former senior HHS official. "That's something the Trump administration was pilloried for allegedly doing." One clear sign of that politicization, several legal and medical experts said, is the guidance's double standard between race and sex. Men in the United States have proven to be about 60 percent more likely than women to die of the disease, according to research from the Brookings Institution, and within some age brackets the mortality gap is even larger. But the FDA doesn't list sex as a risk factor anywhere in its guidance. And while the Utah scheme does take it into account, the New York and Minnesota schemes do not. Nor do they or the FDA give any weight to geography and socioeconomic status, both of which are associated with COVID-19 mortality. Instead, the triage plans give more weight to race than to many comorbidities. In Minnesota's scoring system, "BIPOC status" is worth two points, the same as diabetes and cardiovascular disease, whereas "hypertension in a patient 55 years and older" is worth just one. In Utah's scoring system, "Non-white race or Hispanic/Latinx ethnicity" is worth two points—the same amount as diabetes, obesity, and "severely immunocompromised"—while hypertension, congestive heart failure, chronic pulmonary disease, and "shortness of breath" count for one each. Men do receive one extra point under the Utah scheme, on the grounds that "male gender is associated with increased risk of severe COVID-19." Nonbinary patients, the document says, "may choose to answer" questions about their gender identity "with that background information." Speaking of Woke medicine… Microsoft WORD Will Now Offer Woke Corrections https://notthebee.com/article/microsoft-word-introduces-new-woke-feature-to-monitor-your-language?fbclid=IwAR0sxOqYrccyxxhgAfuKMSuVVCtBFRRQaHfC8qs1PZ3HmOtL4S6PU6Z8DAE From Not the Bee: Microsoft has just introduced a woke, politically correct feature that I don't think anyone ever asked for… Traditionally, Microsoft Word has been used by its 250 million users for things such as spelling, punctuation, and grammar checks. But that wasn't enough for the tech giant. They (probably) thought, "spelling and grammar checks are great and all but what we really want to do is influence and control the masses." Control is the biggest rave these days. Word will now highlight no-no words with a purple line beneath any problematic words or phrases that focus on gender, age, sexual orientation, ethnicity or even "socioeconomic status." Red lines are for spelling errors. Green lines for grammar mistakes. And now, purple lines are politically correct language police alerts. If you type a bigoted word like, let's say... "postman," Word will offer less offensive, gender-neutral alternatives like "mail carrier" or "postal worker." The software also suggests altering astronaut Neil Armstrong's famous quote from "one giant leap for mankind," to "humankind" or "humanity" instead. Who knew Neil Armstrong was such a sexist bigot... Microsoft Word knew. In the lyrics to Barry Manilow's party favourite Copacabana, Microsoft suggests Lola be referred to as a "dancer," "performer" or "performing artist" rather than a "showgirl." Word is not just policing your language (and by default, your thoughts) but it seems as though Microsoft wants us to re-write and re-imagine history by suggesting we change famous quotes. It also proposes changing "maid" to "house cleaner." Other changes include "headmaster" (Word suggests "principal"), "mistress" ("lover"), "master" ("expert"), "manpower" ("workforce") and "heroine" ("hero"). This isn't the first time Microsoft is cracking down on language, and it probably won't be the last! Just last year, Microsoft 365 tried to filter swearing and "bad behavior." Microsoft was also ridiculed in November over a video presentation showing senior execs introducing themselves by citing their race and gender pronouns. Marketing manager Nic Fillingham was filmed saying: "I'm a Caucasian man with glasses and a beard. I go by he/him." The Reformed Sage DNB: Founded in 2018, The Reformed Sage exists to edify Christians with products and services that build the kingdom of God and proclaim the gospel to all. We have created products that are unique, useful, beautiful, and humorous. We have wood art, engraved wall art, apparel, drinkware, decals, stamps, and much more. We also regularly make custom merchandise at wholesale prices for churches, ministries and businesses that want to add or expand their product offerings in turn increasing revenue. Please use promo code FLF22 for 10% off your first order. AND HAPPENING NOW: All apparel is marked down until Super Bowl Sunday! (No promo code necessary) Shirts: $20 Hoodies: $30 and more! They are changing apparel vendors and removing some designs. We do not know at this time what color/sizing options we will have available come March 1. So, if there is an apparel combo you want (design/size/color) better grab it before it is gone for good! This sale ends on February 6th. Next up from a listener – and remember you can send stories that you think we should cover on these Daily News Briefs to news@crosspolitic dot com.  A Federal Agency Has Begun Collecting Names & Religious Exemption Records https://www.washingtontimes.com/news/2022/jan/11/biden-administration-planning-lists-employees-seek/ The Washington Times reports: An obscure federal agency has proposed creating a database capturing the names and “personal religious information” of government employees who submit “religious accommodation requests” to be exempted from the Biden administration's COVID-19 vaccine mandate. At least seven other federal agencies, including five Cabinet departments, are apparently setting up similar “personal religious information” databases, according to an analyst at the Heritage Foundation, a conservative think tank in the District. The federal Court Services and Offender Supervision Agency for the District of Columbia, or CSOSA, published a “notice of a new system of records” in the Federal Register on Tuesday. The agency, which supervises defendants awaiting trial as well as parolees, aims to “reduce recidivism” and “integrate offenders into the community by connecting them with resources and interventions.” The federal departments of Treasury, the Interior, Housing and Urban Development, Health and Human Services, and Transportation, as well as the General Services Administration and the Securities and Exchange Commission, have each published proposed rule-makings to implement “systems of records” tracking their workers' religious accommodation requests. While there is “some data collection that is likely and legally permissible under Title VII, when an individual at a covered agency requests a religious accommodation,” Sarah Parshall Perry, a legal fellow at the Heritage Foundation's Institute for Constitutional Government, said, “we have not seen it on a broad scale like this ever.” President Biden's COVID-19 vaccine mandate for federal workers took effect Nov. 22 under an executive order he issued Sept. 9. The executive order said its terms were “subject to such exceptions as required by law.” “We're not clear on what personal religious information is going to be gathered” under the CSOSA proposal, Ms. Perry said, adding that numerous sticky questions will come up. “How does one as a federal agency determine the sincerity or lack thereof of an individual's religious beliefs?” she asked rhetorically. “Normally, information like that goes directly to the [Equal Employment Opportunity Commission] and is maintained for internal purposes, just in the case that there is a future dispute about whether or not religious discrimination exists. However, we're not told why or how this information is being used. And that smacks of religious discrimination on a grand scale.” Psalm of the Day: 23 0:20-0:54, 3:33-4:11 The King of Love my shepherd is…  Good Shepherd, may I sing thy praise, within thy house forever.  Amen. Remember you can always find the links to our news stories and these psalms at crosspolitic dot com – just click on the daily news brief and follow the links. Or find them on our App: just search “Fight Laugh Feast” in your favorite app store and never miss a show.  This is Toby Sumpter with Crosspolitic News. A reminder: Support Rowdy Christian media, and share this show or become a Fight Laugh Feast Club Member. What allows us to continuing growing to take on the Big Media Lie Fest is your monthly membership support. If you've already joined, a huge thanks to you, and if you haven't, please consider joining today and have a great weekend.

Play during opening: 0:00-0:10 …and more on today's CrossPolitic Daily News Brief. This is Toby Sumpter. Today is Friday, January 14, 2022. SCOTUS Blocks Biden VAX Mandate & Upholds Healthcare Worker Mandate https://www.cnbc.com/2022/01/13/supreme-court-ruling-biden-covid-vaccine-mandates.html The Supreme Court on Thursday blocked the Biden administration from enforcing its sweeping vaccine-or-test requirements for large private companies, but allowed a vaccine mandate to stand for medical facilities that take Medicare or Medicaid payments. The rulings came three days after the Occupational Safety and Health Administration's emergency measure for businesses started to take effect. The mandate required that workers at businesses with 100 or more employees get vaccinated or submit a negative Covid test weekly to enter the workplace. It also required unvaccinated workers to wear masks indoors at work. “Although Congress has indisputably given OSHA the power to regulate occupational dangers, it has not given that agency the power to regulate public health more broadly,” the court wrote in an unsigned opinion. “Requiring the vaccination of 84 million Americans, selected simply because they work for employers with more than 100 employees, certainly falls in the latter category,” the court wrote. President Joe Biden, in a statement, said the Supreme Court chose to block requirements that are life-saving for workers. Biden called on states and businesses to step up and voluntarily institute vaccination requirements to protect workers, customers and the broader community. “The Court has ruled that my administration cannot use the authority granted to it by Congress to require this measure, but that does not stop me from using my voice as President to advocate for employers to do the right thing to protect Americans' health and economy,” Biden said. In a separate, simultaneously released ruling on the administration's vaccination rules for health-care workers, a 5-4 majority sided with the Biden administration. “We agree with the Government that the [Health and Human Services] Secretary's rule falls within the authorities that Congress has conferred upon him,” said the majority, writing that the rule “fits neatly within the language of the statute.” “After all, ensuring that providers take steps to avoid transmitting a dangerous virus to their patients is consistent with the fundamental principle of the medical profession: first, do no harm,” the majority opinion read. Justices Clarence Thomas, Samuel Alito, Neil Gorsuch and Amy Coney Barrett, four of the six conservatives on the nine-seat bench, dissented. Kavanaugh and Roberts joined the three liberals to enforce this ruling. “I do not think that the Federal Government is likely to be able to show that Congress has authorized the unprecedented step of compelling over 10,000,000 healthcare workers to be vaccinated on pain of being fired,” Alito wrote in his dissent. FDA Issues Racist Triage Rationing for COVID Treatments https://freebeacon.com/coronavirus/food-and-drug-administration-drives-racial-rationing-of-covid-drugs/ Fron the Washington Free Beacon: In New York, racial minorities are automatically eligible for scarce COVID-19 therapeutics, regardless of age or underlying conditions. In Utah, "Latinx ethnicity" counts for more points than "congestive heart failure" in a patient's "COVID-19 risk score"—the state's framework for allocating monoclonal antibodies. And in Minnesota, health officials have devised their own "ethical framework" that prioritizes black 18-year-olds over white 64-year-olds—even though the latter are at much higher risk of severe disease. These schemes have sparked widespread condemnation of the state governments implementing them. But the idea to use race to determine drug eligibility wasn't hatched in local health departments; it came directly from the federal Food and Drug Administration. When the FDA issued its emergency use authorizations for monoclonal antibodies and oral antivirals, it authorized them only for "high risk" patients—and issued guidance on what factors put patients at risk. One of those factors was race. The FDA "fact sheet" for Sotrovimab, the only monoclonal antibody effective against the Omicron variant, states that "race or ethnicity" can "place individual patients at high risk for progression to severe COVID-19." The fact sheet for Paxlovid, Pfizer's new antiviral pill, uses the Centers for Disease Control and Prevention's definition of "high risk," which states that "systemic health and social inequities" have put minorities "at increased risk of getting sick and dying from COVID-19." The guidance sheets are nonbinding and do not require clinicians to racially allocate the drugs. But states have nonetheless relied on them to justify race-based triage. "The FDA has acknowledged that in addition to certain underlying health conditions, race and ethnicity ‘may also place individual patients at high risk for progression to severe COVID-19,'" Minnesota's plan reads. "FDA's acknowledgment means that race and ethnicity alone, apart from other underlying health conditions, may be considered in determining eligibility for [monoclonal antibodies]." Utah's plan contains similar language. In a section on the "Ethical Justification for Using Race/Ethnicity in Patient Selection," it notes that the FDA "specifically states that race and ethnicity may be considered when identifying patients most likely to benefit from this lifesaving treatment." The FDA declined to comment on either state's plan, saying only that "there are no limitations on the authorizations that would restrict their use in individuals based on race." The triage plans are part of a broader push to rectify racial health disparities through race-conscious means. In March of last year, for example, two doctors at Brigham and Women's Hospital in Boston outlined an "antiracist agenda for medicine" that involved "offering preferential care based on race." And last year, Vermont and New Hampshire both gave racial minorities priority access to the COVID-19 vaccine, resulting in at least one formal civil rights complaint against New Hampshire. The trend has alarmed Roger Severino, the former civil rights director at the Department of Health and Human Services, who called racial preferences in medicine a "corrosive and grossly unfair" practice. "Our civil rights laws are not suspended during a public health emergency," Severino said. "We should never deny someone life-saving health care because of the color of their skin." The triage plans show how federal guidelines can encourage this sort of race discrimination. They also suggest that the FDA is making political judgments, not just scientific ones. "They're injecting politics into science," said a former senior HHS official. "That's something the Trump administration was pilloried for allegedly doing." One clear sign of that politicization, several legal and medical experts said, is the guidance's double standard between race and sex. Men in the United States have proven to be about 60 percent more likely than women to die of the disease, according to research from the Brookings Institution, and within some age brackets the mortality gap is even larger. But the FDA doesn't list sex as a risk factor anywhere in its guidance. And while the Utah scheme does take it into account, the New York and Minnesota schemes do not. Nor do they or the FDA give any weight to geography and socioeconomic status, both of which are associated with COVID-19 mortality. Instead, the triage plans give more weight to race than to many comorbidities. In Minnesota's scoring system, "BIPOC status" is worth two points, the same as diabetes and cardiovascular disease, whereas "hypertension in a patient 55 years and older" is worth just one. In Utah's scoring system, "Non-white race or Hispanic/Latinx ethnicity" is worth two points—the same amount as diabetes, obesity, and "severely immunocompromised"—while hypertension, congestive heart failure, chronic pulmonary disease, and "shortness of breath" count for one each. Men do receive one extra point under the Utah scheme, on the grounds that "male gender is associated with increased risk of severe COVID-19." Nonbinary patients, the document says, "may choose to answer" questions about their gender identity "with that background information." Speaking of Woke medicine… Microsoft WORD Will Now Offer Woke Corrections https://notthebee.com/article/microsoft-word-introduces-new-woke-feature-to-monitor-your-language?fbclid=IwAR0sxOqYrccyxxhgAfuKMSuVVCtBFRRQaHfC8qs1PZ3HmOtL4S6PU6Z8DAE From Not the Bee: Microsoft has just introduced a woke, politically correct feature that I don't think anyone ever asked for… Traditionally, Microsoft Word has been used by its 250 million users for things such as spelling, punctuation, and grammar checks. But that wasn't enough for the tech giant. They (probably) thought, "spelling and grammar checks are great and all but what we really want to do is influence and control the masses." Control is the biggest rave these days. Word will now highlight no-no words with a purple line beneath any problematic words or phrases that focus on gender, age, sexual orientation, ethnicity or even "socioeconomic status." Red lines are for spelling errors. Green lines for grammar mistakes. And now, purple lines are politically correct language police alerts. If you type a bigoted word like, let's say... "postman," Word will offer less offensive, gender-neutral alternatives like "mail carrier" or "postal worker." The software also suggests altering astronaut Neil Armstrong's famous quote from "one giant leap for mankind," to "humankind" or "humanity" instead. Who knew Neil Armstrong was such a sexist bigot... Microsoft Word knew. In the lyrics to Barry Manilow's party favourite Copacabana, Microsoft suggests Lola be referred to as a "dancer," "performer" or "performing artist" rather than a "showgirl." Word is not just policing your language (and by default, your thoughts) but it seems as though Microsoft wants us to re-write and re-imagine history by suggesting we change famous quotes. It also proposes changing "maid" to "house cleaner." Other changes include "headmaster" (Word suggests "principal"), "mistress" ("lover"), "master" ("expert"), "manpower" ("workforce") and "heroine" ("hero"). This isn't the first time Microsoft is cracking down on language, and it probably won't be the last! Just last year, Microsoft 365 tried to filter swearing and "bad behavior." Microsoft was also ridiculed in November over a video presentation showing senior execs introducing themselves by citing their race and gender pronouns. Marketing manager Nic Fillingham was filmed saying: "I'm a Caucasian man with glasses and a beard. I go by he/him." The Reformed Sage DNB: Founded in 2018, The Reformed Sage exists to edify Christians with products and services that build the kingdom of God and proclaim the gospel to all. We have created products that are unique, useful, beautiful, and humorous. We have wood art, engraved wall art, apparel, drinkware, decals, stamps, and much more. We also regularly make custom merchandise at wholesale prices for churches, ministries and businesses that want to add or expand their product offerings in turn increasing revenue. Please use promo code FLF22 for 10% off your first order. AND HAPPENING NOW: All apparel is marked down until Super Bowl Sunday! (No promo code necessary) Shirts: $20 Hoodies: $30 and more! They are changing apparel vendors and removing some designs. We do not know at this time what color/sizing options we will have available come March 1. So, if there is an apparel combo you want (design/size/color) better grab it before it is gone for good! This sale ends on February 6th. Next up from a listener – and remember you can send stories that you think we should cover on these Daily News Briefs to news@crosspolitic dot com. A Federal Agency Has Begun Collecting Names & Religious Exemption Records https://www.washingtontimes.com/news/2022/jan/11/biden-administration-planning-lists-employees-seek/ The Washington Times reports: An obscure federal agency has proposed creating a database capturing the names and “personal religious information” of government employees who submit “religious accommodation requests” to be exempted from the Biden administration's COVID-19 vaccine mandate. At least seven other federal agencies, including five Cabinet departments, are apparently setting up similar “personal religious information” databases, according to an analyst at the Heritage Foundation, a conservative think tank in the District. The federal Court Services and Offender Supervision Agency for the District of Columbia, or CSOSA, published a “notice of a new system of records” in the Federal Register on Tuesday. The agency, which supervises defendants awaiting trial as well as parolees, aims to “reduce recidivism” and “integrate offenders into the community by connecting them with resources and interventions.” The federal departments of Treasury, the Interior, Housing and Urban Development, Health and Human Services, and Transportation, as well as the General Services Administration and the Securities and Exchange Commission, have each published proposed rule-makings to implement “systems of records” tracking their workers' religious accommodation requests. While there is “some data collection that is likely and legally permissible under Title VII, when an individual at a covered agency requests a religious accommodation,” Sarah Parshall Perry, a legal fellow at the Heritage Foundation's Institute for Constitutional Government, said, “we have not seen it on a broad scale like this ever.” President Biden's COVID-19 vaccine mandate for federal workers took effect Nov. 22 under an executive order he issued Sept. 9. The executive order said its terms were “subject to such exceptions as required by law.” “We're not clear on what personal religious information is going to be gathered” under the CSOSA proposal, Ms. Perry said, adding that numerous sticky questions will come up. “How does one as a federal agency determine the sincerity or lack thereof of an individual's religious beliefs?” she asked rhetorically. “Normally, information like that goes directly to the [Equal Employment Opportunity Commission] and is maintained for internal purposes, just in the case that there is a future dispute about whether or not religious discrimination exists. However, we're not told why or how this information is being used. And that smacks of religious discrimination on a grand scale.” Psalm of the Day: 23 0:20-0:54, 3:33-4:11 The King of Love my shepherd is… Good Shepherd, may I sing thy praise, within thy house forever. Amen. Remember you can always find the links to our news stories and these psalms at crosspolitic dot com – just click on the daily news brief and follow the links. Or find them on our App: just search “Fight Laugh Feast” in your favorite app store and never miss a show. This is Toby Sumpter with Crosspolitic News. A reminder: Support Rowdy Christian media, and share this show or become a Fight Laugh Feast Club Member. What allows us to continuing growing to take on the Big Media Lie Fest is your monthly membership support. If you've already joined, a huge thanks to you, and if you haven't, please consider joining today and have a great weekend.

The Omicron variant is by far the most dominant of the COVID virus strains in our region at this time. Dr. John Zurlo, Chief of Infectious Diseases updates us on what we're seeing in the hospitals, new monoclonal antibody therapies Sotrovimab and Evusheld, and the accuracy of at-home tests. Plus, he addresses whether the United States will follow in the footsteps of Germany and Israel and expedite an additional booster. Be sure to check out The Health Nexus for additional content on COVID like an update on boosters, floosters, and the omicron variant.   Follow Jefferson Health: @TJUHospital on Twitter @JeffersonHealth on Instagram @JeffersonHospital on Facebook    

- Dịch Covid-19 tại Australia tiếp tục lan rộng khi hôm nay ghi nhận hơn 36 nghìn ca bệnh mới. Trong bối cảnh dịch Covid-19 lây lan nhanh chưa từng có, chính phủ Australia vừa quyết định mua thêm thuốc Sotrovimab để điều trị các bệnh nhân Covid-19 có triệu chứng nhẹ và vừa. Tác giả : Việt Nga/VOV Australia Chủ đề : Australia, kỷ lục, covid --- Support this podcast: https://anchor.fm/vov1thegioi/support

From today, a new treatment for vulnerable patients at greater risk of Covid-19 is being offered at London hospitals.The drug, called Sotrovimab, has been manufactured by GlaxoSmithKline, which says it appears to work against the Omicron variant, and can cut the risk of hospitalisation or death by almost 80 per cent.Medicine Development Lead for the drug Dr Amanda Peppercorn explains how the drug works, how effective it is against Omicron, and why it is so significant in the fight against Covid-19. See acast.com/privacy for privacy and opt-out information.

CommonSpirit Health Physician Enterprise EVP, Dr. Thomas McGinn discusses the new Omicron COVID-19 variant, recently published research and recent awards.

❗⁠您的一杯咖啡錢 = 我們遠大的目標！捐款支持我們：https://pse.is/3jknpx

În cadrul ediției de pe 23 noiembrie 2021 a emisiunii #știința360 de pe Radio România Cultural, Dr. Marius Geantă, Președintele Centrului pentru Inovație în Medicină #inomed, a comentat topul săptămânal Esențial Covid-19 de pe Raportuldegardă.ro, precum și conceptul de social prescribing: îmbunătățirea stării de sănătate prin schimbări de natură socială. Administrarea unei doze de #sotrovimab, în primele 5 zile de infecție COVID-19, ar putea scădea riscul de a dezvolta o formă severă a bolii. Agenția Europeană a Medicamentului a început evaluarea acestui anticorp monoclonal, în vederea autorizării condiționate. În plus, EMA a debutat și evaluarea datelor disponibile asupra altui candidat terapeutic, #Paxlovid. Mai mult, Comitetul pentru Produse Medicale de Uz Uman (CHMP) din cadrul EMA recomandă autorizarea în Uniunea Europeană a antiviralului #molnupiravir (Lagevrio), pentru reducerea riscului de evoluție severă COVID-19 la pacienții cu factori de risc în acest sens. Mai multe detalii - https://bit.ly/3HYnM9Z și https://raportuldegarda.ro/stiri-covid-romania/ „Social prescribing” (prescripția socială, tradus mot-a-mot) reprezintă un concept care nu își are corespondentul în sistemul de sănătate din România și se referă la posibilitatea ca medicul curant să recomande pacientului o serie de activități de natură socială, care ar putea să-i îmbunătățească starea de sănătate. Cu alte cuvinte, acest serviciu, recunoscut la nivelul sistemului de sănătate din Regatul Unit al Marii Britanii (NHS), este dovada faptului că în anumite cazuri, îmbunătățirea stării de sănătate poate fi obținută prin schimbări de natură socială ale stilului de viață și nu prin măsuri farmacologice sau clinice. Mai multe detalii - https://bit.ly/3p2dGMD

During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.Key points include:Treatment of COVID-19 can be broken into antiviral and immune-modulating therapiesEach agent should be used at the correct disease stage to maximize benefitAntiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mountedPassive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized personsOperational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systemsPresenter:Lynora Saxinger, MD, FRCPC, CTropMedCochair, Scientific Advisory Group  Alberta COVID-19 Emergency Coordination Centre  Associate ProfessorDivision of Infectious DiseasesDepartment of Medicine  University of AlbertaEdmonton, Alberta, CanadaContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Follow along with the slides at:https://bit.ly/3BxQKtD Link to full program:https://bit.ly/3BwzdlC

Experts say the "logistics" of giving the medication may mean it will not be available in many rural and regional areas.

In a major step towards controlling COVID-19, the American drug company Merck has developed an antiviral pill found to be effective against the virus. Clinical trials show the pill halved the risk of hospitalisation or death when given to high-risk people early in their infections.

A neurologist is warning a new anti-body treatment used to fight Covid, shouldn't be used as a substitute for vaccination.  The TGA has granted provisional approval for Sotrovimab to be used in Australians at-risk of being hospitalised with the virus.  Doctor Robin Fitzsimons has told Luke Grant, it dramatically brings down the risk of death from the disease.  Click play below to listen to the interview.   See omnystudio.com/listener for privacy information.

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:Rationale for use of mAbPotential for resistance to mAbSingle vs combination therapy with mAbChallenges in implementation of mAb as treatment or preventionBamlanivimabSotrovimabCasirivimab plus imdevimabLink to full program, including downloadable slidesets:  https://bit.ly/3zVTwYWPresenters: Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesFaculty Medicine Dentistry and Health SciencesUniversity of Melbourne and Royal Melbourne HospitalConsultant Infectious Diseases PhysicianDepartment of Infectious DiseasesRoyal Melbourne Hospital and Alfred HospitalMelbourne, AustraliaArthur Kim, MDAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Viral Hepatitis ClinicDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsSharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor.

[Entrevista em Inglês] Stefan de Keersmaecker, porta-voz da Comissão Europeia para a Saúde, explica o porquê da aposta da instituição no Sotrovimab - medicamento para o tratamento precoce da doença. See omnystudio.com/listener for privacy information.

Sotrovimab es un anticuerpo monoclonal que está específicamente dirigido contra la proteína de pico del SARS-CoV-2 y está diseñado para bloquear la unión del virus y su entrada en las células humanas. Los datos que respaldan esta autorización del uso de emergencias para sotrovimab se basan en un análisis intermedio de un ensayo clínico de fase 1/2/3 aleatorizado, doble ciego y controlado con placebo. El cual se resume en 8 puntos: 1-Participaron 583 adultos no hospitalizados con síntomas de COVID-19 de leves a moderados y un resultado positivo de la prueba de SARS-CoV-2. 2-De estos pacientes, 291 recibieron sotrovimab y 292 recibieron un placebo dentro de los cinco días posteriores al inicio de los síntomas de COVID-19. 3-El criterio de valoración principal fue la progresión de COVID-19 (definida como hospitalización durante más de 24 horas para el tratamiento agudo de cualquier enfermedad o muerte por cualquier causa) hasta el día 29. 4-La hospitalización o muerte se produjo en 21 (7%) pacientes que recibieron placebo en comparación 3 (1%) pacientes tratados con sotrovimab, una reducción del 85%. 5-Las pruebas de laboratorio mostraron que el sotrovimab conserva la actividad frente a las variantes circulantes actuales que se notificaron por primera vez en el Reino Unido, Sudáfrica, Brasil, California, Nueva York e India. 6-La EUA permite que el sotrovimab sea distribuido y administrado como una dosis única de 500 miligramos por vía intravenosa por parte de los proveedores de atención médica. 7-Los posibles efectos secundarios de sotrovimab incluyen anafilaxia y reacciones relacionadas con la infusión, erupción cutánea y diarrea. 8-Sotrovimab no está autorizado para pacientes hospitalizados o que requieran oxigenoterapia debido a COVID-19. Este tratamiento no ha mostrado beneficio en estos pacientes y pueden estar asociados con peores resultados clínicos cuando se administran a pacientes hospitalizados que requieren alto flujo de oxígeno o ventilación mecánica. REFERENCIA https://www.sotrovimab.com/content/dam/cf-pharma/hcp-sotrovimab/sotrovimab-fda-letter-of-authorization.pdf https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-EUA.PDF#nameddest=HCPFS https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19 https://www.ema.europa.eu/en/documents/referral/sotrovimab-also-known-vir-7831-gsk4182136-covid19-article-53-procedure-conditions-use-conditions_en.pdf ADAPTACION PARA AUDIO-OYENTES: Medicina en una página. ================================================ PODCAST CORONAVIRUS. COVID-19 Este es un podcast en el que desde el ojo de la ciencia. Aprenderemos del coronavirus y de la enfermedad covid-19. Recuerden al enemigo es mejor conocerlo. Para acabarlo. Esta es una producción de: Medicina en una página. medicinaenunapagina@gmail.com Dirección y Conducción: John Jarbis García Tamayo. Médico y cirujano, Epidemiólogo y Pedagogo Universitario.